Professor Cheng Ying talks about the progress and development trend of small cell lung cancer treatment.

the !---- 15th CSCO Changbai Oncology Summit Was successfully held online.over the years, under the leadership of the Chinese Society of Clinical Oncology (CSCO), the CSCO Changbai Oncology Summit Forum has become a high-profile academic event in China's oncology community.at this year's conference, more than 100 top experts who have deep knowledge in the field of cancer research gathered to give lectures and celebrate. During themeeting, I had the honor to interview Professor Cheng Ying of Jilin Cancer Hospital to share the development of the Changbai Cancer Summit Forum and take stock of the latest research progress of small cell lung cancer.Cheng Ying, second-level professor, doctoral tutor, postdoctoral workstation tutor, director of Jilin Cancer Center, director of Jilin Cancer Center, vice president of the Chinese Society of Clinical Oncology (CSCO), chairman of the CSCO Small Cell Lung Cancer Professional Committee, cSCO Clinical Research Expert Committee-designate, CSCO Deputy Chairman of the Non-Small Cell Lung Cancer Professional Committee, Deputy Chairman of the CSCO Committee of Experts on Liver Cancer, Deputy Chairman of the CSCO Big Data Expert Committee, Vice Chairman of the China Anticancer Association's Lung Cancer Professional Committee, Vice Chairman of the Chinese Cancer Association's Cancer Society's Professional Committee on Cancer Clinical Chemotherapy, Member of the Oncology Credit Committee of the Chinese Medical Association, and Deputy Chairman of the National PhysicianS Professional Editorial Committee on The Regular Assessment of Oncology. CSCO Changbai Cancer Summit Forum CSCO Changbai Oncology Summit Forum is one of CSCO's very important brand academic conference, but also the largest academic event in the field of oncology in Northeast China, the conference was preceded by CSCO New Progress Learning Class, CSCO Northeast Regional Forum, mainly to continue education and standardized training for the original intention, later renamed CSCO Changbai Cancer Summit Forum, radiation nationwide, hope to provide a broader learning platform for cancer specialists nationwide to further enhance the level of learning and communication. After 15 years of painstaking construction and cultivation, thehas evolved from the most basic follow-up conference to a high-level academic discussion conference.CSCO Changbai Cancer Summit Forum has been adhering to the "followed education and academic emphasis" concept, whether at the expert level or topic settings and other aspects are very attentive, that is, to take into account the training and education of primary doctors, but also pay attention to the dissemination of new progress, new information, every year will give the national tumor with a rich content, comprehensive academic event.during this period we have also been the country's top experts strong support, the honor to invite the top experts in the field of cancer at home and abroad to teach, including our CSCO chairman, vice-chairman, secretary-general, under-secretary-general, the main committee of the ad hoc committee, vice-chairman, etc. , each expert is carefully prepared, with unique insights and profound knowledge for you to present a wonderful academic feast.lecture content also covers the current lung cancer, breast cancer, digestive tract tumor, gynaecological tumor and other diseases, so that students do not have to run a number of special sessions, in a venue to hear the knowledge of multi-tumor species, this has also been recognized by experts and students and praise.in addition, our success can not be separated from the support of the vast number of students, from the initial few hundred people to attend the meeting, the development of thousands of people.this year due to the outbreak, the meeting changed to the offline start-up and online broadcast of the special way held, but did not reduce the enthusiasm of the participants, the national students are actively online watching, let us also be encouraged, but also gave us the confidence to continue to run the meeting.important progress in the field of small cell lung cancer in the first half of 2020, progress in the field of small cell lung cancer is still concentrated in immunotherapy.the latest results from three studies on first-line treatment for immunotherapy.THE CASPIAN STUDY FOLLOWED UP 25.1 MONTHS, OS MATURITY REACHED 82%, THE LATEST RESULTS SHOW THAT THE OS OF THE DEGREE OF VALU MONOTENING COMBINATION CHEMOTHERAPY IS STILL SIGNIFICANTLY BETTER THAN CHEMOTHERAPY (MEDIAN OS: 12.9 VS 10.5 MONTHS, HR 0.75, P-0.0032), CAN REDUCE THE RISK OF DEATH BY 25%, THE RESULTS OF THE UPDATE DID NOT SHAKE THE SCALE OF THE U.S.another STUDY THIS YEAR, THE CASPIAN STUDY ALSO REPORTED RESULTS FROM THE TREATMENT GROUP OF 4 DRUGS, WHICH FOUND THAT NEITHER PFS NOR OS WERE BETTER THAN CHEMOTHERAPY AND INCREASED TOXICITY.another important broad-period small cell lung cancer immunofirst treatment phase III study is the KEYNOTE-604 study, the KEYNOTE-604 study is a Paboli zuma sepsal combined chemotherapy and placebo combined chemotherapy control randomized phase III study, this study using sequential sequence test statistical design, mid-term analysis first test PFS, PFS to meet statistical assumptions before testing OS.the study in the medium-term PFS analysis, the median PFS of the Paboli zuma supretic combination chemotherapy group and the chemotherapy group were 4.5 months and 4.3 months, respectively, meeting the preset P-value (P-0.0023), but in the final analysis, the OS of paboli zumas-combined chemotherapy group did not reach the pre-set P-doranuclear-based chemotherapy group, suggesting that the OS of Pabolizumab anti-chemotherapy did not achieve a statistically significant improvement. this year there was also a phase II study of navuriu monoto-statin combined chemotherapy and chemotherapy control, and only PFS benefited without significant improvement in OS. different studies of first-line immunotherapy of small cell lung cancer presentdifferent results considered with the study population, research design, drug differences, follow-up treatment and other factors, suggesting that immunotherapy in small cell lung cancer has more exploration, including the selection of markers and the exploration of treatment patterns. immunotherapy has also made new advances in the study of recurrent small cell lung cancer. presented a phase II study of Carelli zumas in the treatment of extensive small cell lung cancer at the 2020 AACR conference, which showed that carellizumab in SCLC second-line therapy showed that the Carelli beads single anti-apprealitas in SCLC second-line therapy The ORR of Tinib was 33.9%, the median OS was 8.4 months, and even in drug-resistant patients, the median OS reached 8.0 months, suggesting that immunocombination anti-angiogenesis therapy was a promising treatment strategy for recurrent small cell lung cancer. in the field of chemotherapy for small cell lung cancer, there were also important breakthroughs in the first half of this year. new chemotherapy drug, lurbinectin, has been approved by the U.S. FDA as a standard treatment option for metastatic small cell lung cancer for disease progression after chemotherapy, and the second choice since topological approval in 1996 to receive fda-recommended second-line treatment for small cell lung cancer, and is recommended as a second-line treatment for small cell lung cancer in the newly updated NCCN 2020V4 version of the small cell lung cancer guidelines. the current randomized phase III validation study of Rubicadine in conjunction with topological dysphorus or COA control has also completed the group, and look forward to the results of the phase III Rubicadin second-line treatment of small cell lung cancer confirmed research. anti-angiogenesis treatment drug Anrotini achieved a breakthrough in the third-line and post-line treatment of small cell lung cancer, this year also emerged in the first-line treatment, an Arrotini combined chemotherapy first-line treatment of a wide range of small cell lung cancer phase II patients, preliminary results showed that THE ORR reached 77.78 percent, median PFS 9.61 months. this gives confidence that the ongoing phase III study of the first-line treatment of ES-SCLC with a combination of PD-L1 inhibitors will lead to a breakthrough in first-line therapy. the development trend of small cell lung cancer has been treated as an indiscriminate whole, with the progress of research, people's understanding of small cell lung cancer is deepening, small cell lung cancer molecular distype initially formed, each subtype of small cell lung cancer development mechanism understanding, micro-environmental characteristics of the comprehensive disclosure, small cell lung cancer is also towards the development of type-by-type treatment. immunotherapy has established a new treatment standard for small cell lung cancer, however, the efficacy is still not satisfactory, the exploration of immunotherapy markers, the new immunotherapy strategy research will provide efficient and accurate treatment options for small cell lung cancer. targeted drugs such as PARP inhibitors and Aurora kinase inhibitors are also exploring people who can benefit from them; sCLC genomes are complex, it is difficult to defeat drugs that simply target a pathway or genetically modified drugs, and exploring joint strategies that can act together are also the main exploration directions, and the treatment of small cell lung cancer will change rapidly in the future. Zack Source: Tumor Information !-- End of Content Presentation -- !-- Determine Sending Out.